| Product NDC: | 0007-4640 |
| Proprietary Name: | PROMACTA |
| Non Proprietary Name: | eltrombopag olamine |
| Active Ingredient(s): | 25 mg/1 & nbsp; eltrombopag olamine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0007-4640 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022291 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20081124 |
| Package NDC: | 0007-4640-13 |
| Package Description: | 30 TABLET, FILM COATED in 1 BOTTLE (0007-4640-13) |
| NDC Code | 0007-4640-13 |
| Proprietary Name | PROMACTA |
| Package Description | 30 TABLET, FILM COATED in 1 BOTTLE (0007-4640-13) |
| Product NDC | 0007-4640 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | eltrombopag olamine |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20081124 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | ELTROMBOPAG OLAMINE |
| Strength Number | 25 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Increased Megakaryocyte Maturation [PE],Increased Platelet Production [PE],Thrombopoiesis Stimulating Agent [EPC],Thrombopoietin Receptor Agonists [MoA],Thrombopoietin Receptor Interactions [MoA] |